EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Comment on: Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients

Federico Barone, Andrea Giacomelli iD, Giacomo Casalini, Mario Corbellino, Alessia Lai iD, Andrea Gori, Spinello Antinori iD

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae234 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Federico Barone und 6 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Scienze Biomediche e Cliniche, Università degli Studi di Milano, Milan, Italy. Hauptthemen laut MEDLINE: Adenosine Monophosphate, Alanine, Antiviral Agents, COVID-19 Drug Treatment. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenosine MonophosphateAlanineAntiviral AgentsCOVID-19 Drug TreatmentImmunocompromised HostSARS-CoV-2Drug Therapy, CombinationHumansCOVID-19Antibodies, Monoclonal, HumanizedTreatment OutcomeAdenosine

Substanzen

remdesivirAdenosine MonophosphateAlanineAntiviral AgentsAntibodies, Monoclonal, HumanizedGS-441524Adenosine

Autor:innen und Institutionen

  • Dipartimento di Scienze Biomediche e Cliniche, Università degli Studi di Milano, Milan, Italy.
  • III Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy.
  • II Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy.
  • Centre for Multidisciplinary Research in Health Science (MACH), Università degli Studi di Milano, Milan, Italy.

ORCID-Profile: Andrea Giacomelli, Alessia Lai, Spinello Antinori

Zitieren

APA

Barone, F., Giacomelli, A., Casalini, G., Corbellino, M., Lai, A., Gori, A., & Antinori, S. (2024). Comment on: Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae234

Vancouver

Barone F, Giacomelli A, Casalini G, Corbellino M, Lai A, Gori A, et al. Comment on: Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae234

BibTeX
@article{Barone2024,
  author = {Barone, Federico and Giacomelli, Andrea and Casalini, Giacomo and Corbellino, Mario and Lai, Alessia and Gori, Andrea and Antinori, Spinello},
  title = {Comment on: Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae234}
}
Kostenlos starten →